11 recalls found for Fresenius Kabi USA, LLC. Check if any of your products are affected.
Fresenius Kabi USA, LLC recalls 5% Dextrose Injection, USP 12.5 g per 250 mL in FreeFlex bags due to lack of sterility assurance. The recall covers units distributed nationwide including Alaska and Puerto Rico. Healthcare providers and patients should stop use and consult a healthcare professional.
Lack of Assurance of Sterility
Fresenius Kabi USA, LLC recalls 5% Dextrose Injection, USP IV solution in freeflex bags due to lack of assurance of sterility. The recall affects batches 6402399, 6402400, and 6402401 with Exp 02/28/2027. Distributors nationwide, including Alaska and Puerto Rico, are notified. Stop using and contact the company for guidance and potential replacement.
Fresenius Kabi USA recalled 0.9% Sodium Chloride Injection nationwide, including Alaska and Puerto Rico. The recall is due to lack of assurance of sterility. Healthcare providers should stop using the product immediately and contact Fresenius Kabi for guidance.
Fresenius Kabi USA recalled saline injections distributed nationwide, including Alaska and Puerto Rico. The action covers multiple batch numbers with sterility concerns. Healthcare providers and patients should stop using the product immediately and follow official guidance for replacement options.
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Fresenius Kabi USA, LLC recalled 5% Dextrose Injection, USP, 50 mL in a 100 mL freeflex bag, distributed nationwide including Alaska and Puerto Rico. The recall cites lack of assurance of sterility. Consumers and healthcare providers should stop using this product immediately and contact Fresenius Kabi for guidance.
Fresenius Kabi USA, LLC recalls 2,199,850 vials of Famotidine Injection, U.S. distribution nationwide plus Alaska, Hawaii and Puerto Rico after endotoxin testing concerns. The microbial contamination risk prompted an immediate stop-use order. Healthcare providers and patients should follow recall guidance and seek alternatives through their providers.